20:54 , Dec 19, 2017 |  BC Innovations  |  Distillery Therapeutics

Ophthalmic disease

INDICATION: Diabetic retinopathy Patient samples and mouse studies suggest inhibiting EPHX2 could help treat non-proliferative diabetic retinopathy (NPDR). In postmortem retinal tissue samples from patients, high levels of EPHX2 were associated with disease severity. In a...
19:02 , Nov 27, 2017 |  BC Innovations  |  Distillery Therapeutics

Renal

INDICATION: Renal damage Mouse studies suggest 14,15-epoxyeicosatrienoic acid (EET) or inhibition of its catabolic enzyme EPHX2 could help treat acute kidney injury (AKI). In a mouse model of AKI, 14,15-EET decreased kidney injury and increased survival...
15:59 , Apr 25, 2017 |  BC Innovations  |  Distillery Therapeutics

Dental

INDICATION: Periodontitis Studies in mice suggest inhibiting epoxide hydrolase could help treat periodontal bone loss. In a mouse model of bacterial infection-induced periodontitis, a previously reported epoxide hydrolase inhibitor decreased alveolar bone loss compared with vehicle....
08:00 , Dec 3, 2015 |  BC Innovations  |  Targets & Mechanisms

The two faces of LTA4H

Although the enzyme LTA4H has long been considered a driver of inflammatory diseases, companies have yet to create an inhibitor that succeeds in the clinic beyond Phase II. That could be due to a secondary,...
07:00 , Aug 18, 2014 |  BioCentury  |  Strategy

Breathing room

AstraZeneca plc's acquisition of Almirall S.A.'s respiratory assets should buy the pharma time while its respiratory pipeline matures. The deal not only gives AstraZeneca a faster route to market in the COPD combination therapy race...
07:00 , Jun 19, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Hypertension Epoxide hydrolase Mouse studies identified a soluble epoxide hydrolase-dependent mechanism by which a Mediterranean diet...
07:00 , Apr 25, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Epoxide hydrolase 2 (EPHX2; CEH) Cell culture and mouse studies suggest a combination of fish oil-derived...
07:00 , Apr 4, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Cardiovascular disease Epoxide hydrolase 2 (EPHX2; CEH) Mouse studies suggest epoxide...
07:00 , Jul 19, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Diabetic neuropathy; pain Epoxide hydrolase Rat studies suggest inhibitors of soluble epoxide...
08:00 , Jan 12, 2012 |  BC Innovations  |  Targets & Mechanisms

EETing away at metastasis

U.S. researchers have shown that antagonizing epoxyeicosatrienoic acids, a type of fatty acid metabolite, reduces tumor growth and metastasis in mice.1 The challenge will be finding a dose that has the desired effect without impairing...